Rapid hemodilution induced by desmopressin after erythropoietin administration in humans

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10045/17817
Información del item - Informació de l'item - Item information
Título: Rapid hemodilution induced by desmopressin after erythropoietin administration in humans
Autor/es: Sanchís Gomar, Fabián | Martínez Bello, Vladimir E. | Derbré, Frédéric | García López, Ernesto | García Vallés, Rebeca | Brioche, Thomas | Ferrando, Beatriz | Ibáñez Sania, Sandra | Pareja Galeano, Helios | Gómez Cabrera, María del Carmen | Viña, José
Palabras clave: Hemoglobin | Hematocrit | Reticulocytes | Stimulation index and plasma volume expanders
Área/s de conocimiento: Educación Física y Deportiva
Fecha de publicación: 2011
Editor: Universidad de Alicante. Área de Educación Física y Deporte
Cita bibliográfica: SANCHÍS GOMAR, Fabián, et al. “Rapid hemodilution induced by desmopressin after erythropoietin administration in humans”. Journal of Human Sport and Exercise [en línea]. Vol. 6, No. 2 (2011). Supplement. ISSN 1988-5202, pp. 315-322. http://www.jhse.ua.es/index.php/jhse/article/viewArticle/225 [consulta: 29 junio 2011]
Resumen: We have shown that treatment with desmopressin has a very effective hemodilution effect in healthy humans. These results led us to suggest the possible role of desmopressin to mask blood doping in sports. Based on our results, the World Anti-Doping Agency included the desmopressin in the 2011 List of Prohibited Substances and Methods. On this occasion, the aim of our study was to test the desmopressin-induced hemodilution after rHuEpo administration in humans. This was an intra-subject, crossover study in which five physically active males acted as their own controls. A basal blood sample was taken on their first visit to the laboratory. The next day, the subjects began the treatment. They received a subcutaneous rHuEpo injection three times/week for a two-week period. On the second visit to the laboratory, seventeen days later, a blood sample was taken. Thereafter, the subjects received an oral dose of 4.3 μg/kg of desmopressin and were instructed to ingest 1.5 liters of mineral water during the following fifteen minutes. Three hours after the water ingestion a second blood sample was obtained. The samples were analyzed for hematocrit (HCT), hemoglobin (Hb), reticulocytes (Ret%) and OFF Hr-Score. We found significantly higher HCT, Hb and Ret% levels after rHuEpo administration. Administration of desmopressin significantly decreased the HCT and Hb values but we did not find significant changes in Ret%. The values of the OFF Hr-Score also decreased after treatment with desmopressin. Desmopressin has a very effective hemodilution effect after rHuEpo administration and significantly modifies the hematological values measured by the anti-doping authorities to detect blood doping. We consider that these results reinforce the conclusions reported in our first study and confirm that desmopressin is a very effective masking agent for blood doping.
Patrocinador/es: This work was supported by grants SAF2008-00270; SAF2009-08334; BFU2007-65803/BFI; from the Spanish Ministry of Education and Science (MEC); PROMETEO/2010/074 from the Consellería de Educación de la Generalitat Valenciana. ISCIII2006-RED13-027 from the “Red Temática de investigación cooperativa en envejecimiento y fragilidad (RETICEF)”, EU Funded COSTB35 and DPS2008-06968 from Spanish Ministry of Innovation and Science. This study has been co-financed by FEDER funds from the European Union.
URI: http://hdl.handle.net/10045/17817
ISSN: 1988-5202
DOI: 10.4100/jhse.2011.62.12
Idioma: eng
Tipo: info:eu-repo/semantics/article
Revisión científica: si
Versión del editor: http://dx.doi.org/10.4100/jhse.2011.62.12
Aparece en las colecciones:Revistas - Journal of Human Sport and Exercise - 2011, Vol. 6, No. 2. Supplement

Archivos en este ítem:
Archivos en este ítem:
Archivo Descripción TamañoFormato 
Thumbnailjhse_Vol_VI_N_II_315-322.pdf388,31 kBAdobe PDFAbrir Vista previa

Este ítem está licenciado bajo Licencia Creative Commons Creative Commons